Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dapsone + tazarotene is a combination of two topical pharmaceutical agents: dapsone, a synthetic sulfone with anti-inflammatory and antibacterial properties, and tazarotene, a synthetic retinoid. This combination is used primarily in the treatment of acne vulgaris, targeting both comedonal and inflammatory acne lesions. Dapsone acts by inhibiting neutrophil myeloperoxidase and suppressing inflammation, while tazarotene modulates gene expression to normalize keratinocyte differentiation and reduce follicular hyperkeratinization. Clinical evidence supports improved efficacy for comedonal acne compared to tazarotene monotherapy. Both components are applied topically and individually approved by regulatory agencies for acne indications[1][5][7][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dapsone + tazarotene.